HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
Social Factors Likely Explain Colon Ca Racial Disparities
After controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis.
HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
Zanzalintinib Combo Improves Survival in Pretreated Metastatic CRC
Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.
FDA Grants Fast Track Designation to NG-350A for pMMR Rectal Cancer
Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
Zanzalintinib Combo Improves Survival in Pretreated Metastatic CRC
Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.
FDA Grants Fast Track Designation to NG-350A for pMMR Rectal Cancer
Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.